Key details Current treatment limitations: While ischaemic strokes – which account for nearly 90% of all strokes – are currently treated with clot removal and supportive rehabilitation, there remains a significant unmet need for therapies that directly address...
Key details New trial approval: The South Korean Ministry of Food and Drug Safety has approved a Phase 2a trial for a new umbilical cord stem cell therapy to treat Charcot-Marie-Tooth disease (CMT), one of the most commonly inherited nerve diseases.[1] Promising phase...
Key details Understanding Lesch-Nyhan syndrome: This rare, recessive condition linked to the X chromosome primarily affects boys, and is characterized by a deficiency of the HPRT enzyme, leading to severe motor dysfunction, uric acid overproduction, and compulsive...
Today is World Cord Blood Day! A lot of progress has been made since the very first cord blood transplant was performed in 1988, 37 years ago. Since then, over 60,000 cord blood transplants have been performed worldwide, and cord blood stem cells have become the...
A recent study conducted at UMC Utrecht, Netherlands, has shown that mesenchymal stem cells (MSCs) are a safe treatment for brain damage caused by stroke in newborns, and could have a significant positive effect. Perinatal stroke and its consequences Perinatal stroke...
A groundbreaking therapy based on transplanting mitochondria into blood stem cells has shown encouraging results in an ongoing, phase 2 trial. If successful, the therapy could not only treat rare, incurable diseases, but also potentially help reverse some of the...
